Licorice flavonoid oil (LFO), which contains hydrophobic flavonoids from Glycyrrhiza glabra LINNE, is a new ingredient for functional foods. In this study, we investigated the anti-obesity action of LFO in dietinduced obese rats. The addition of 2% LFO in a highfat diet significantly decreased the weight of abdominal adipose tissue and the levels of hepatic and plasma triglycerides. We found that the enzymatic activities of acetyl-CoA carboxylase and fatty acid synthase, the rate-limiting enzymes in the fatty acid synthetic pathway, were significantly decreased by LFO, whereas the enzymatic activity of acyl-CoA dehydrogenase, the ratelimiting enzyme in the fatty acid oxidative pathway, was significantly increased. All our findings suggest that the anti-obesity action of LFO is controlled by regulation of the rate-limiting enzymes in the fatty acid synthetic and oxidative pathways in the liver.
There is evidence that decreases in abdominal fat mass aids patients with metabolic syndrome. 3) Hence new drugs and food ingredients that effectively suppress the accumulation of abdominal fat should be developed for pharmacotherapy or alimentotherapy for the syndrome.
Recently, much attention has been focused on plant flavonoids that might be beneficial in reducing the risk of obesity. 4) For example, dietary catechins and anthocyanins significantly decrease the weight of abdominal adipose tissues. 5, 6) Investigation of the metabolic effects of plant flavonoids might lead to more effective strategies for the treatment of obesity.
Licorice, the root of the leguminous Glycyrrhiza plant species, has been used medicinally for the past 4,000 years. 7, 8) There are several species of licorice, including Glycyrrhiza uralensis FISCHER, G. glabra LINNE, and G. inflate BATALIN, and each of which contains speciesspecific flavonoids. 9, 10) Licorice flavonoid oil (LFO), which contains hydrophobic flavonoids from G. glabra LINNE, is a new ingredient for functional foods. [9] [10] [11] [12] We recently found that LFO decreases the size of hepatic lipid droplets, which are mainly composed of triglyceride (TG), and abdominal adipose tissue weight in diet-induced obese mice. 10) It is well-known that TG is synthesized in the liver, secreted into the blood-stream, and transported to the peripheral organs, including the adipose tissues. 13, 14) The hepatic TG content is significantly correlated with plasma TG level and fat mass in humans. 15) The hepatic TG availability is controlled by the balance between fatty acid synthesis and oxidation in the liver. 16) Hence we hypothesized that LFO suppresses fatty acid synthesis and/or promotes fatty acid oxidation in the liver, which in turn results in decreases in the concentrations of hepatic and plasma TGs and the weight of abdominal fat.
In this study, we focused on the anti-obesity action of LFO in diet-induced obese rats as a model system because the fatty acid synthetic and oxidative pathways are well-established. [17] [18] [19] Our results suggest that LFO suppresses abdominal fat accumulation by regulation of rate-limiting enzyme activities related to fatty acid synthesis and oxidation in the liver.
Materials and Methods
Preparation of licorice flavonoid oil (LFO). Licorice can cause the side effects such as hypermineralocortiy To whom correspondence should be addressed. Fax: +81-78-803-5808; E-mail: hasegawa@kobe-u.ac.jp Abbreviations: ACC, acetyl-coenzyme A carboxylase; ACD, acyl-coenzyme A dehydrogenase; FAS, fatty acid synthase; LFO, licorice flavonoid oil; LDL, low density lipoprotein; MCT, medium-chain triglycerides; PPAR-, peroxisome proliferator-activated receptor-; SREBP-1, sterol regulatory element-binding protein 1; TG, triglyceride; TNF-, tumor necrosis factor-; VLDL, very low density lipoprotein coidism 20) and pseudoaldosteronism. 21) They have been ascribed to the inhibitory activity of glycyrrhizic acid from licorice on 11-hydroxy-steroid dehydrogenase. 21) Hence we prepared LFO (Kaneka, Osaka, Japan), which contains glycyrrhizic acid at below 0.005%, as follows: 12) Powdered root of licorice (Glycyrrhiza glabra LINNE) was extracted with five volumes of 95% ethanol twice, then filtered, concentrated, and treated with activated charcoal. After additional filtration and concentration, ethanol extract was further extracted with medium-chain triglycerides (MCT; C8:C10 = 99:1, Riken Vitamin, Tokyo), then concentrated and filtered to separate insolubles. Consequently, the LFO contained licorice ethanolic extract at 10% and MCT at 90%. The yield of licorice ethanolic extract in terms of the starting dried plant material was about 9% (w/w). The flavonoid content in the LFO was measured by HPLC assay, as described previously.
11) The concentration of glabridin, the major flavonoid in licorice, was 1% in the LFO.
Animals, diets, and experimental design. Male Sprague-Dawley rats, 5 weeks old, were obtained from Charles River Laboratories Japan (Yokohama, Japan), and were housed individually in stainless steel wiremesh cages at 25 C in a room with an automatically controlled 12-h light:dark cycle. Upon arrival, the rats were fed a nonpurified diet (MF, Oriental Yeast, Tokyo) and acclimated to the facility for 7 d before feeding of the experimental diets. The rats had free access to water and the assigned diets for the length of each experiment. Body weights were measured once a week and feed intake was measured every day. At the end of each experimental period, the rats were deprived of food for 8 h and then anesthetized with an intraperitoneal injection of sodium pentobarbital (5 mg/100 g body weight). Abdominal adipose tissue (epididymis, perirenal, and mesenteric adipose tissue) was excised and weighed.
Three experiments were designed to examine the effects of LFO on abdominal adipose tissue weight, plasma lipid concentrations, and hepatic lipid metabolism in diet-induced obese rats, as follows: In a preliminary experiment, the rats were fed a normal diet or a high-fat diet. In experiment 1, they were fed a highfat diet or a high-fat diet containing LFO at 0.5, 1.0 or 2.0%. In experiment 2, they were fed a high-fat diet or a high-fat diet containing LFO at 2.0%. All experimental procedures followed the guidelines for the care and use of experimental animals at the Rokkodai Campus of Kobe University in Japan.
Preliminary experiment. The rats were randomly divided into two groups and fed a normal diet or a high-fat diet ( Table 1 ). The normal diet was used to evaluate the efficacy of the induction of obesity with the high-fat diet. The compositions of the normal diet were the same as the high-fat diet ( Table 1 ), except that soybean oil was replaced with corn starch. The concentrations of soybean oil and corn starch in the normal diet were 6.000% and 51.497% respectively. Blood was collected from the carotid arteries. Plasma was separated immediately by centrifugation at 3;000 Â g for 10 min at 4 C, frozen with liquid nitrogen, and stored at À80 C for plasma insulin analysis. Experiment 1. The rats were randomly divided into four groups and fed a high-fat diet or a high-fat diet containing LFO at 0.5, 1.0, or 2.0% (Table 1) for 21 d. When the diet was supplemented with LFO, the LFO was added at the expense of the oil mixture, which contained 90% MCT and 10% soybean oil. Consequently, the MCT concentration in each diet was 1.8%. Plasma was separated and frozen as described above for plasma TG analysis. The liver was excised, weighed, frozen immediately with liquid nitrogen, and stored at À80 C for lipid analysis. Experiment 2. The rats were randomly divided into two groups and fed a high-fat diet or a high-fat diet containing LFO at 2.0% (Table 1) for 21 d. Plasma was separated and frozen as described above for plasma lipids, insulin, and glucose analysis. The liver was excised and weighed. A portion of the fresh liver was frozen immediately in liquid nitrogen and stored at À80 C for lipid analysis. Another portion of the fresh liver was used to prepare mitochondria 22) and cytosol 23) fractions. The liver was homogenized in 9 volumes of 10 mM phosphate buffer (pH 7.0), 0.3 M sucrose, and 1 mM EDTA. The homogenate was centrifuged at 750 Â g for 5 min at 4 C, and the supernatant was recentrifuged at 10;000 Â g for 10 min at 4 C. The resulting pellet (hepatic mitochondria fraction) was frozen with liquid nitrogen and stored at À80 C for enzymatic analysis. The supernatant was recentrifuged at 105;000 Â g for 60 min at 4 C. The resulting supernatant (hepatic cytosol fraction) was frozen with liquid nitrogen, and stored at À80 C for enzymatic analysis.
Analytical methods. Plasma and hepatic lipid analyses. The total lipid of each liver was extracted from the frozen liver with chloroform-methanol (2:1, vol/vol). The lipid extract was dried, dissolved in 2-propanol, and used in the analyses of TG, cholesterol, and phospholipids. Very low density lipoprotein (VLDL) was isolated from the frozen plasma by the method of Cham.
24) Plasma, VLDL, and hepatic TG levels were determined enzymatically using commercial kits (Triglyceride E-test Wako, Wako Pure Chemical Industries, Osaka, Japan). Plasma and hepatic total cholesterol levels were determined enzymatically using commercial kits (Cholesterol E-test Wako, Wako Pure Chemical Industries). Plasma and hepatic phospholipid levels were determined by the method of Bartlett.
25)
Enzymatic analyses. The acetyl-CoA carboxylase (ACC) activity in the hepatic cytosol fractions was determined by H 14 CO 3 À fixation assay. 26) The fatty acid synthase (FAS) activity in hepatic cytosol fractions was determined by the spectrophotometric method.
23) The acyl-CoA dehydrogenase (ACD) activity in hepatic mitochondria fractions was determined by the method of Mason et al.
27) The protein concentrations in the mitochondria and cytosol fractions were determined by the method of Lowry et al.
28)
Plasma insulin and glucose analyses. The plasma insulin concentration was determined using a commercial ELISA kit (Rat Insulin ELISA Kit, Shibayagi, Gunma, Japan). The plasma glucose concentration was determined enzymatically using a commercial kit (Glucose CII-test Wako, Wako Pure Chemical Industries).
Statistical methods. The data from experiment 1 were analyzed by the Tukey-Kramer test. The data from the other experiments were analyzed by Student's t test. All statistical analyses were performed using a commercial package (StatView version 5, SAS Institute, Cary, NC, 1998).
Results

Preliminary experiment
The rats fed the high-fat diet showed significantly (p < 0:05) greater body weight gain (116%) and development of abdominal adipose tissue (124%) than those fed the normal diet (data not shown), indicating that the high-fat diet induced obesity. The plasma insulin concentration of the high-fat diet group was significantly (p < 0:01) higher than that of the normal diet group (193%, data not shown). Based on these results, the high-fat diet (Table 1 ) was used in experiments 1 and 2.
Experiment 1
The results are shown in Table 2 . The addition of 2.0% LFO in the high-fat diet significantly (p < 0:05) decreased the weight of abdominal adipose tissue (71.0%), which was composed of epididymal, perirenal, and mesenteric adipose tissues. Each of these three adipose tissue weights was significantly (p < 0:05) decreased in the high-fat diet + 2.0% LFO group (60.4%, 66.2% and 89.5% respectively). The addition of 2.0% LFO to the high-fat diet significantly (p < 0:05) decreased the hepatic TG concentration (71.6%). The addition of 1.0 and 2.0% LFO to the high-fat diet significantly (p < 0:05) decreased the plasma TG concentration (45.6% and 40.9% respectively). There were no significant differences in final body weight, body weight gain, or feed intake among groups. Since the addition of 2.0% LFO to the high-fat diet decreased abdominal adipose tissue weight and the levels of hepatic and plasma TGs, the high-fat diet and the highfat diet containing 2.0% LFO (Table 1) were used in experiment 2.
Experiment 2
The effects of dietary LFO on body weight, feed intake, abdominal adipose tissue weight, and hepatic and plasma lipid components are shown in Table 3 . The addition of 2.0% LFO to the high-fat diet significantly (p < 0:01) decreased the abdominal adipose tissue weight (71.5%). The epididymal, perirenal, and mesen- There were no significant differences in final body weight, body weight gain, feed intake, or plasma or hepatic phospholipid concentrations among the groups. As shown in Figs. 1 and 2 , LFO significantly (p < 0:05) decreased ACC and FAS activity (70.5% and 72.4% respectively), and significantly (p < 0:01) increased ACD activity (207.0%) in the liver. As Fig. 3 shows, LFO significantly decreased the plasma insulin (p < 0:05) and glucose (p < 0:01) concentrations (64.8% and 82.3% respectively).
Discussion
In this study, we found that LFO significantly decreased both abdominal adipose tissue weight and the plasma TG concentration (Tables 2 and 3 ). In addition, the plasma total cholesterol concentration tended to decrease in the high-fat diet + 2% LFO group (Table 3) . Hence LFO might serve as a drug or food ingredient to prevent or ameliorate obesity and hyperlipidemia.
LFO significantly decreased abdominal adipose tissue weight and effectively decreased TG levels in the liver and plasma, and VLDL (Table 3) . As mentioned in the introduction, TGs are synthesized in the liver, secreted into the bloodstream mainly as VLDL, and transported to the peripheral organs, including adipose tissues. 13, 14) VLDL formation is highly dependent on TG availability in the liver. 16 ) Hepatic TG availability is altered by the balance between fatty acid synthesis and oxidation in the liver. 16) Hence we examined the enzymatic activities of the rate-limiting enzymes related to fatty acid synthesis and oxidation in the liver, and found that the enzymatic activities of ACC and FAS, the rate-limiting enzymes of the fatty acid synthetic pathway, were significantly decreased by LFO, whereas the enzymatic activity of ACD, the rate-limiting enzyme of the fatty acid oxidative pathway, was significantly increased (Figs. 1  and 2 ). These findings suggest that LFO decreases hepatic and plasma TG levels by regulation of ratelimiting enzymes involved in fatty acid synthesis and oxidation in the liver, which in turn results in decreases in abdominal adipose tissue weight. Also, it is possible that inhibition of dietary fat absorption is involved in the anti-obesity action of LFO, but the addition of a very low level (0.2%) of licorice ethanolic extract to the highfat diets (more than 27% fat), apparently reduced the abdominal adipose tissue weight by approximately 30% (Table 3) . Such a large decrease in abdominal adipose tissue under the high-fat diet is difficult to explain by inhibition of dietary fat absorption. As shown in Figs. 1 and 2, we found that LFO apparently decreases the ratelimiting enzymes of the fatty acid synthetic pathway and increases the rate-limiting enzyme of the fatty acid oxidative pathway in the liver. Thus it appears that the anti-obesity effect of LFO is due mainly to regulation of lipid metabolism in the liver.
We also found that LFO significantly reduces the plasma insulin concentration in diet-induced obese rats (Fig. 3) . Insulin is known to upregulate sterol regulatory element-binding protein 1 (SREBP-1) mRNA levels, 29) and Steineger et al. have reported that insulin strongly downregulates peroxisome proliferator-activated receptor-(PPAR-) mRNA levels in both normal rat hepatocytes and hepatoma cells in vitro.
30) SREBP-1 and PPAR-are transcription factors for fatty acid synthetic and fatty acid oxidative enzymes respectively. 31, 32) Thus it appears that the decrease in insulin concentration due to LFO observed in the current study might downregulate SREBP-1 and upregulate PPAR-.
Several adipokines, such as tumor necrosis factor-(TNF-) and resistin, induce insulin resistance and raise blood glucose levels. 33) There is evidence that plasma TNF-and resistin concentrations positively correlate with body fat mass. [34] [35] [36] [37] In this study, dietary LFO significantly decreased plasma glucose and insulin concentrations and abdominal adipose tissue weight ( Fig. 3 and Table 3 ). Thus it is possible that the decrease in the plasma concentration of TNF-and/or resistin due to anti-obesity action of LFO reduced the plasma glucose concentration, which in turn resulted in a low plasma insulin concentration in the rats fed the high-fat diet containing 2.0% LFO (Fig. 3) . Further studies are required to address this possibility.
In conclusion, we examined the effects of dietary LFO on abdominal fat accumulation and plasma and hepatic TG metabolism in diet-induced obese rats. Our findings indicate that LFO significantly decreases the weight of abdominal adipose tissue and the levels of plasma and hepatic TG, and suggest that the anti-obesity action of LFO can be controlled by decreasing the ratelimiting enzymes of the fatty acid synthetic pathway and increasing the rate-limiting enzyme of the fatty acid oxidative pathway in the liver. Thus the natural ingredient LFO is a promising candidate for a drug or food ingredient to prevent or ameliorate obesity, the most prevalent manifestation of metabolic syndrome. Data represent the mean AE SEM for eight rats in each group. Ã;ÃÃ Significant with respect to high-fat diet group (p < 0:05 and p < 0:01).
